

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Methods, Para 3-4, Line 133, 142	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No cell lines are used.	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	No cell lines are used.	n/a
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	This is a study related with human, no animals are used.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	This is a study related with human, no animals are used.	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID	This is a study related with human, no animals are used.	
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	No plants are used.	n/a
Microbes: provide species and strain, unique accession number if available, and source	No plants are used.	n/a
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods, Para 1, Line 114-115	
Provide statement confirming informed consent obtained from study participants.	Methods, Para 1, Line 114-115	
Report on age and sex for all study participants.	Results, Para 1, Line 198-203	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	This not a laboratory study.	n/a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		n/a
Sample size determination	No pre-grouping, no sample size determined	n/a
Randomisation	No pre-grouping, no randomisation required	n/a
Blinding	No pre-grouping, no blinding required	n/a
Inclusion/exclusion criteria	Methods, Para 1, Line 108-114	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	This was not study of experiments	n/a
Define whether data describe technical or biological replicates	This was not study of experiments	n/a
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods, Para 1, Line 114-115 Footnotes, Ethical Statement, L409-410	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This not animal study.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	This not experiments about specimen and field samples	n/a
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	No dual use of any other research	n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Methods, Para 1, Line 108-114	n/a
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Methods, Para 7, Line 187-194	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a
If data are publicly available, provide accession number in repository or DOI or URL.	Data is about patient privacy, and is not publicly available. The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Data is about patient privacy, and is not publicly available. The data sets used and/or analyzed during the current study are available from the corresponding	n/a
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	No such use of code or software.	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	No such use of code or software.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	The authors have completed the MDAR reporting checklist.	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: <https://dx.doi.org/10.21037/atm-22-3161>